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Abstract
Prognostic markers, such as NPM1, Flt3-ITD, and cytogenetic abnormalities have made it possible to formulate 
aggressive treatment plans for unfavorable acute myeloid leukemia (AML). However, the long-term survival of AML 
with unfavorable factors remains unsatisfactory. The latest data indicate that the standard dose of daunorubicin (DNR) 
at 45 mg/m2 is inferior to high dose 90 mg/m2 for induction therapy. The rates of complete remission and overall 
survival are significantly better in the high dose induction regimen. New regimens exploring the new liposomal 
encapsulation of Ara-C and DNR as well as addition of gemtuzumab ozogamicin monoclonal antibody have been 
studied. New agents, including the nucleoside analogues (clofarabine, sapacitabine, elacytarabine), FLT3 inhibitor 
(sorafenib), farnesyl-transferase inhibitor (tipifarnib), histone deacetylase inhibitor (vorinostat), lenalidomide, as well as 
DNA methyltransferase inhibitors (decitabine, azacitidine), were recently reported for AML treatment in the 2009 ASH 
annual meeting. This review also summarizes the updates of the clinical trials on novel agents including voreloxin, 
AS1413, behenoylara-C, ARRY520, ribavirin, AZD1152, AZD6244, and terameprocol (EM-1421) from the 2009 ASH 
annual meeting.
Introduction
Acute myeloid leukemia (AML) is the most common type
of acute leukemia in adults. Over the past twenty years,
the studies on the pathogenesis and prognosis of AML
have made revolutionary progress. However, only one-
third of adult AML can be cured even to this date. The
treatment of refractory, relapsed and elderly AML
remains a major challenge. In recent years, new regimens
and novel agents are being studied in an effort to improve
complete remission (CR) rate and overall survival. This
study will review the latest advances in AML treatment
and summarize the highlights from the 2009 ASH Annual
Meeting.
New regimens for induction therapy of newly 
diagnosed AML
High dose daunorubicin improves survival
The standard induction regimen for newly diagnosed
AML consists of daunorubicin (DNR) 45 mg/m2 intrave-
nously for 3 days and cytarabine (AraC) 100 mg/m2 by
continuous infusion for 7 days [1]. With this regimen 60%
to 80% of young adults and 40% to 60% of older adults can
achieve a CR.
Several major studies, particularly Cancer and Leuke-
mia Group B (CALGB) 9621 [2,3] and the French ALFA
9000 studies [4], have shown that higher doses of DNR
(80 or 90 mg/m2) can be administered safely. Recently,
there are two major prospective studies compared DNR
90 mg/m2 with 45 mg/m2 in the induction regimen. East-
ern Cooperative Oncology Group (ECOG) studied 657
AML patients between the age of 17 to 60 [5]. The study
showed significantly higher CR rate for patients receiving
90 mg/m2 (70% versus 57%). More importantly, overall
survival (OS) was significantly prolonged (23.7 vs 15.7
months). The Dutch-Belgium Hemato-Oncology Coop-
erative Group (HOVON)/Swiss Group for Clinical Can-
cer Research (SAKK) compared DNR 90 mg/m2 versus 45
mg/m2 in 813 patients older than 60 years [6]. The results
showed that CR rate was 64% and 54% respectively, while
CR rate after only one course of treatment was 52% and
35% respectively. The OS rate was not significantly differ-
ent for the whole group. However, for the patients
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between the age of 60 to 65, the OS rate was significantly
better in the high dose group (38% vs 23%). The rates of
serious adverse events were similar in the two treatment
groups in both studies.
Based on historic trials and the most recent prospective
studies, Rowe points out that 45 mg/m2 of DNR should
no longer be the standard-dose for induction therapy [7].
Instead, for induction therapy of all age groups, DNR
dose should be between 60 mg/m2 to 90 mg/m2 for 3 days,
but the exact optimal dosage remains to be established.
New formulations of old agents
Liposomal encapsulation of drugs can reduce the toxicity
and decrease drug doses with controlled-release effect.
CPX-351 is a liposomal formulation that encapsulates
cytarabine and daunorubicin at a 5:1 molar ratio. A
recently completed phase 1 study recommended that 90-
minute infusions of 101 u/m2 be given on days 1, 3, and 5
(1 u = 1 mg Ara-C + 0.44 mg DNR) [8]. The results
showed that liposomal encapsulation of this chemother-
apy doublet changed the safety profile by reducing non-
hematologic toxicities including hair loss, gastrointestinal
toxicities and hepatic toxicity, while retaining hematopoi-
etic cytotoxicity. A phase IIb randomized study was initi-
ated to compare CPX-351 with conventional DA regimen
(Ara-C + DNR) in AML patients aged 60-75. CPX-351
exhibits an acceptable safety profile for use in older,
newly diagnosed AML patients[9].
Targeted therapy regimens
In recent years, encouraging results have been achieved
by using monoclonal antibodies for targeted therapy of
the solid and hematologic malignancies. CD33 antigen is
expressed in more than 90% of AML cells, while expres-
sion in normal tissue is very weak. Gemtuzumab ozoga-
mycin (GO) is chemoimmunotherapy agent consisting of
a monoclonal antibody against CD33 conjugated to cali-
chemycin. GO triggers apoptosis when hydrolyzed in the
leukemic blasts. GO has been approved by the U.S. FDA
for the treatment of the elderly (> 60 years) with AML in
first relapse [10]. Standard induction regimen with or
w i t h  o u t  G O  w e r e  c o m p a r e d  i n  a  r a n d o m i z e d  s t u d y
which enrolled 1115 younger adults with AML. The
results showed a similar CR rate in both arms, but a sig-
nificantly improved DFS among patients receiving GO--
51% versus 40% at 3 years (P = .008)[11].
GO + chemotherapy is also used in AML with special
chromosome abnormalities. GO + FLAG has been used
to treat 34 cases of newly diagnosed AML younger than
60 with core binding factor (CBF) abnormality [Inv(16) =
10; t(8;21) = 24]. The induction regimen consisted of the
following agents: Fludarabine 30 mg/m2/d, d1-5, Ara-C 2
g/m2/d, d1-5, GO 3 mg/m2/d1, and G-CSF 3 mg/kg/d.
The GO-FLAG regimen in CBF+ AML yielded impressive
clinical and molecular response in 29 of the 34
patients[12].
A phase II study of My-FLAI aiming to assess toxicity
and efficacy was done in patients with newly diagnosed
AML aged more than 60 years. Fifty-one patients were
enrolled with a median age of 68 years. Twenty-five
patients had a secondary AML and 31% had a complex
karyotype. Fludarabine (25 mg/m2), cytarabine (1 g/m2),
and idarubicin (5 mg/m2) were administered for three
consecutive days. GO (5 mg) was infused at day four.
Twenty-seven patients achieved a CR and 4 obtained a
partial response for an overall response rate (ORR) of
61%. The results showed that the four drug regimen My-
FLAI was well tolerated in an elderly AML population,
but its efficacy did not appear to be superior to that of
standard "3+7" regimen[13].
New regimens for refractory/relapsed AML
High-dose cytarabine (HiDAC) is commonly used for
induction of relapsed or refractory AML. At the 2009
ASH meeting, Sarah et al reported a novel, timed-
sequential regimen that takes advantage of synergy when
mitoxantrone is given after cytarabine [14]. It was a retro-
spective analysis of patients with relapsed or refractory
high-risk AML. Those patients received HiDAC/mitox-
antrone regimen, with cytarabine at 3 gm/m2 over four
hours on days 1 and 5 plus mitoxantrone at 30 mg/m2
over one hour immediately following the HiDAC on days
1 and 5. HiDAC/mitoxantrone induction was well toler-
ated and demonstrated an overall response rate of 55%
with induction death rate of 9%.
To further enhance the CR rate in refractory/relapsed
AML, the Japanese Adult Leukemia Study Group
(JALSG) reported a phase II study of FLAGM (Fludara-
bine + High-Dose Ara-C + G-CSF + mitoxantrone) in 41
patients with relapsed or refractory AML. The patients
were treated with fludarabine 15 mg/m2 twice daily (d1-
4), Ara-C 2 g/m2 (d1-4), G-CSF 300 μg/m2 (d1-4), and
mitoxantrone 10 mg/m2 (d3-5). FLAGM yielded a 70%
response rate in either relapsed or refractory AML
patients. Although randomized studies are still needed,
FLAGM appears to be a good option for the treatment of
either relapsed or refractory AML patients [15].
Thomas et al conducted a retrospective analysis of
response (CR and CRi) and survival for patients with first
relapsed AML treated with either IHDAraC or IHDAraC
+ GO regimen [16]. Univariate analysis showed that
IHDAraC +GO induction, as compared with IHDAraC,
was associated with a better response rate (68% vs 48%, p
= 0.08), a lower relapse rate (31% vs 66%, p = 0.02), a bet-
ter overall survival (median 35 months vs 19 months, p =
0.02) and a better event free survival (median not reached
vs 10 months, p = 0.02).Zhu et al. Journal of Hematology & Oncology 2010, 3:17
http://www.jhoonline.org/content/3/1/17
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New Agents
Nucleoside analogues
Nucleoside analogues transform into active metabolites
(triphosphate nucleoside analogues) in the cells and
inhibit DNA synthesis. Clofarabine is a new nucleoside
analogue, a potent inhibitor of both ribonucleotide
reductase and DNA polymerase. At the 2009 ASH meet-
ing, a few studies on clofarabine were reported, either
clofarabine alone or in combination with low-dose Ara-
C, or high-dose Ara-C with the monoclonal antibody GO
in the treatment of elderly AML or relapsed AML [17-
21]. Two novel nucleoside analogues, sapacitabine and
elacytarabine, were also reported for the therapy of the
elderly with refractory or relapsed AML [22,23] (Table 1).
In a preliminary study, twenty patients with relapsed/
refractory AML were enrolled to receive a regimen
including intermediate dose Ara-C, clofarabine and GO
[17]. The preliminary results was 10 of 20 (50%) patients
achieved a complete remission, 1/20 a partial response, 7/
20 had resistant disease, 2/20 died of complications dur-
ing the aplastic phase. Further studies are warranted
(Table 1).
In a single-arm, multi-center, phase II, open-label trial,
112 patients of previously untreated AML, ≥ 60 years old,
and with at least one unfavorable prognostic factor were
enrolled to receive single agent clofarabine [18]. In
patients ≥ 70 y (n = 69), ORR was 39%, CR 33%; In
patients with unfavorable cytogenetics(n = 62), ORR was
42%, CR 32%. Patients with 2 unfavorable prognostic fac-
tors (n = 45) had ORR of 51%. Patients with 3 unfavorable
factors (n = 40) had ORR 38%. Patients ≥ 70 with inter-
mediate or unfavorable karyotype (n = 25) had ORR 48%
and CR 40%; in patients ≥ 70 with unfavorable karyotype
(n = 9) ORR and CR were 56%. Patients ≥ 70 with both
AHD and unfavorable karyotype (n = 18), ORR was 33%
and CR 22%. In patients ≥ 70 with AHD and intermediate
karyotype (n = 8), ORR and CR were 63% (Table 1). It
therefore appears that single agent clofarabine has rea-
sonable activity in newly diagnosed elderly AML patients.
There was another report of a phase II trial which
enrolled 38 patients with relapsed or refractory AML.
The patients received a regimen with G-CSF priming,
clofarabine and high dose Ara-C (GCLAC) [19]. The CR
was 45% and the CR +CRp rate was 64%. These rates were
50% CR and 65% CR+CRp among 1st salvage patients
(95% CI 41-85%), respectively, and 70% CR + CRp exclud-
ing patients who relapsed after allogeneic SCT (Table 1).
It is important to point out that the relatively higher CR
rate could be in part due to the higher dose of AraC.
Clofarabine was tested in a phase I, dose escalation
study in fourteen patients with relapsed and refractory
AML, who received clofarabine in combination with frac-
tionated GO in 2 cohorts. The MTD of clofarabine in
combination with fractionated GO is 20 mg/m2/day for 5
days [20] (Table 1).
Forty patients with AML were enrolled in a phase II
study to receive clofarabine plus low-dose Ara-C induc-
tion followed by consolidation with clofarabine plus low-
dose Ara-C alternating with decitabine. Of the 34
patients evaluable for response, 20 (59%) achieved CR
and 2 (6%) CRp for an overall response rate (ORR) of 65%.
The therapy achieves high response rate with a manage-
able toxicity profile and low induction mortality in elderly
patients with previously untreated AML [21](Table 1).
Table 1: Nucleoside analogues in clinical trials
Study Agents Other agents Disease Dosage Clinical 
trails
No Pts Response Reference
Clofarabine HD Cytarabine, Relapsed and 
refractory AML
22,5 mg/m2 i.v qd, d1-5
GO 6 mg/m2 d6
Phase II 20 CR 50% [17]
Clofarabine Elderly AML 20-30 mg/m2
i.v qd, d1-5
Phase II 112 CR 33-56% [18]
Clofarabine HD Cytarabine Relapsed and 
refractory AML
25 mg/m2/d 1-5d Phase I II 38 CR 45% [19]
Clofarabine GO Relapsed and 
refractory AML
20 mg/m2/d or 30 mg/m2/d d1-5 Phase I 14 MTD: 20 mg/m2 
clofarabine
[20]
Clofarabine LD Cytarabine Elderly untreated 
AML
20 mg/m2 i.v qd, d1-5 Phase II 40 CR 59%
CRp 6%
[21]
Sapacitabine Elderly Relapsed 
and refractory AML
200 or 300 mg po bid ×7d, 400 mg 
po bid ×3d/w ×2w
Phase II 60 CR 10% [22]
Elacytarabine Relapsed and 
refractory AML
2,000 mg/m2 CIV d1-5q3w Phase II 61 CR 15% [23]
Abbreviations: GO: gemtuzumab ozogamycin; HD: high dose; LD, low dose; CRp: CR without platelet recovery; MTD: maximal tolerated dose;Zhu et al. Journal of Hematology & Oncology 2010, 3:17
http://www.jhoonline.org/content/3/1/17
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FLT3 inhibitors (Fms-like tyrosine kinase 3 inhibitors)
The Flt3-internal tandem duplication (ITD) can be found
in approximately 30% of all AML patients and confers a
poor risk status characterized by an increased relapse rate
and poor overall survival [24]. Moreover, Flt3-ITD-posi-
tive AML patients relapsing after allogeneic stem cell
transplantation (SCT) have very limited therapeutic
options. Sorafenib is a multikinase inhibitor that is
approved for the treatment of metastatic renal cell and
hepatocellular carcinoma. A questionnaire was devel-
oped and sent to 28 centers in Germany in order to
obtain more insight into the clinical efficacy and tolera-
bility of sorafenib monotherapy in Flt3-ITD positive
AML. Of the 18 patients treated with sorafenib, five were
primary refractory to induction chemotherapy and 13
were in first (n = 11) or second (n = 2) relapse. Patients
received between 200 mg and 800 mg sorafenib p.o. daily.
The median treatment duration was 98 days (range, 16-
425 days). All patients achieved a hematological response
(HR) characterized by complete (n = 16) or near complete
peripheral blast clearance (n = 2). After a median treat-
ment duration of 180 days (range, 82-270 days), 7 of 18
(39%) patients developed clinical resistance. Therefore,
sorafenib monotherapy has significant clinical activity in
Flt3-ITD positive relapsed and refractory AML [25].
In addition, combination therapy with sorafenib was
shown to be effective in reducing mutant clones in
patients with FLT3 mutations but was not able to com-
pletely eradicate them. These data suggest that sorafenib
can achieve temporary disease control, but should be
integrated into induction and consolidation regimens to
achieve maximal outcome [26-28] (Table 2).
Another retrospective study analyzed sorafenib treat-
ment in 128 patients [26]. Among these patients, twenty-
three patients (18 FLT3-WT, 5 FLT3 mutated) received
FLT3 inhibitors as part of their induction and 9 of them
achieved either CR (n = 6) or CRp (n = 3). These results
suggest that therapy with FLT3 inhibitors has the poten-
tial to improve the outcome of patients with FLT3 muta-
tions (Table 2). Prospective study is needed to confirm
the findings.
In another clinical study, sorafenib was evaluated in 8
AML patients with FLT3+ either prior to or after alloge-
neic stem cell transplantation (allo-SCT) [27]. Two of
four patients who received sorafenib for refractory/
relapsed AML after allo-SCT achieved complete remis-
sion (CR), the other two pts had hematological response.
The rest four patients were treated prior to allo-SCT. Two
of the four relapsed patients showed response to
sorafenib treatment, thereby permitting allo-SCT. One of
these two patients achieved HR, the other had regression
of multiple isolated cutaneous manifestations. Sorafenib
treatment was well tolerated (Table 2).
In a phase II study, eighteen patients with newly diag-
nosed AML and mutated FLT3 were enrolled to receive
sorafenib, idarubicin, and Ara-C [28]. 94% of the patients
achieved a morphological CR/CRp and 6% achieved PR.
This regimen was found to be effective in reducing the
mutant clones (Table 2).
In summary, sorafenib appears to provide a useful
option for treatment of relapsed/refractory AML
patients. However, large prospective study is needed to
confirm the results from the small observational studies.
Farnesyl-transferase inhibitor (FTI)
In recent years, studies have shown that Ras gene muta-
tion plays an important role in leukemogenesis [29]. By
inhibiting farnesyl protein transferase, FTI prohibits the
Ras protein farnesylation, schizolysis and carboxyl meth-
ylation, thus disrupting the critical Ras signaling pathway.
Table 2: FLT3 inhibitors in clinical trials
Study 
Agents
Other agents Disease Dosage Clinical trails No Pts Response Reference
Sorafenib Flt3-ITD+ 
Relapsed and 
refractory AML
200 mg-800 
mg qd
retrospective 26 CHR: 88% [25]
Sorafenib as part of 
induction 
therapy and 
salvage
FLT3+AML, 
untreated 
Relapsed
retrospective 128 CR/CRp: 7% [26]
Sorafenib FLT3+AML
Relapsed and 
refractory
800 mg q.d retrospective 8 CR: 25% [27]
Sorafenib Idarubicin, 
cytarabine
FLT3+AML 
untreated
400 mg po 
bid ×7 d
Phase II 18 CR/CRp: 
94%
[28]
Abbreviations: CR: complete remission; CRp: CR without platelet recovery; CHR: complete hematological responseZhu et al. Journal of Hematology & Oncology 2010, 3:17
http://www.jhoonline.org/content/3/1/17
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A phase II study assessed the efficacy and toxicity of
tipifarnib-bortezomib combination in 80 AML patients
>18 years, unfit for conventional therapy, or >60 years, in
relapse (Table 3). Nine patients (11%) achieved CR, 1
patient had PR, and in 2 cases an hematological improve-
ment (HI) was documented for an overall response rate
(ORR) of 19%. Tipifarnib (± bortezomib) may represent
an important option in a subset of high risk/frail AML
patients [30].
Feldman et al compared efficacy of tipifarnib +/- oral
etoposide with traditional cytarabine/anthracycline-
based induction regimen in older patients with AML.
The results suggest that better CR did not translate into
better survival outcomes (median OS 6.2 vs 7.7 months; p
= 0.82 by log-rank test) [31].
Histone deacetylase inhibitors
Vorinostat is a new anti-cancer agent inhibiting histone
deacetylase and has been shown to have some efficacy in
treatment of AML [32-34]. Vorinostat in combination
with idarubicin and ara-C has synergistic antileukemia
activity in a sequence dependent fashion [35,36]. A phase
II study of vorinostat in combination with idarubicin and
cytarabine as front line therapy for AML or MDS patients
was reported (Table 4). This study enrolled 52 pts at the
time of the report, and 45, all with AML, are evaluable for
response (median age 53 yeas (range 19-65). The CR after
one course of therapy was achieved in 35 pts and 1 pt
achieved a CRp with incomplete platelet recovery for an
overall response rate of 80%. Seven (15%) pts did not
respond to therapy. Therefore, the combination of vor-
inostat, idarubicin and cytarabine is safe and active in
AML[37]. CR or CRi was achieved by 18% pts with MDS,
8% with relapsed/refractory AML, and 36% with
untreated AML; and HI was reported in 9% pts with
MDS, 4% with relapsed/refractory AML, and 8% with
untreated AML.
There was also a preliminary report of a Phase I, open-
label, multicenter, dose-escalating study, designed to
determine the maximum-tolerated dose (MTD) vorinos-
tat combined either concurrently or sequentially with
decitabine in patients (pts) with AML/MDS. 72 patients
were enrolled. CR or CRi (CR with incomplete count
recovery) was achieved by 18% pts with MDS, 8% with
relapsed/refractory AML, and 36% with untreated AML.
Thus, the combination of vorinostat with decitabine,
either concurrently or sequentially, is possible without
significant toxicity, and shows activity in MDS and
untreated AML[38].
DNA Methyltransferase inhibitors
Decitabine inhibits DNA methyltransferase, leading to
DNA hypomethylation and cell differentiation or apopto-
sis. A combination of decitabine and GO was found to be
effective with low side effects in previously untreated or
refractory/relapsed AML patients, especially in elderly
patients[39]. In this phase II study, 33 previously
untreated patients with AML/high-Risk MDS were
enrolled to received GO with decitabine. 24% of the
patients had CR/CRp. Five (15%) patients had clearance
of marrow blasts and 1 patient had hematological
improvement (hemoglobin). The toxicities were minimal
and the regimen can be safely delivered to older patients
(Table 5). In a retrospective study, 79 patients with
relapsed or refractory AML received decitabine/GO
combination. 34% patients responded: 16% CR; 5% CRp;
13% PR-[40]. It is noteworthy that the response rates
from these two studies are similar to that of the single
agent GO, and therefore could be mainly due to the activ-
ity of GO (Table 5)
The French ATU program performed a retrospective
analysis of 184 patients with refractory or relapsed AML
who received azacytidine [41]. 11% of the patients
responded (7%CR,3%CRi,1%PR). It appears that single
agent azacytidine has only limited activity in AML
patients relapsed or refractory to intensive frontline ther-
apy (Table 5).
Combination of azacitidine with bortezomib or low-
dose GO was also studied in relapsed or refractory AML
patients [41-43] (Table 5).
In a retrospective analysis, 56 patients with poor-risk
AML/MDS received treatment with azacitadine and low-
dose GO. 27% of the patients achieved a CR/CRi. An
additional seven patients cleared their peripheral blood
blasts or had hematologic improvement but did not have
remission [42] (Table 5).
In a phase I study, 23 patients with relapsed or refrac-
tory AML were enrolled to receive bortezomib and 5-
azacytidine. The response rate was 26% (6/23) (3-CR, 2-
CRi, and 1-PR). The combination of 5-azacytidine and
bortezomib was well tolerated and appeared to be active
in this cohort of relapsed or refractory AML patients [43]
(Table 5).
In a phase I dose-finding trial, twenty eight patients
with AML/MDS were enrolled to receive vorinostat plus
azacitidine (AZA) in 8 cohorts [44]. Surprisingly, 53% of
the patients achieved CR. In particular, 10 of 12 high-risk
MDS/AML patients (83%) went into CR. This combina-
tion was found to be well tolerated in repetitive cycles.
The optimal dose of AZA in this regimen appears to be
55 mg/m2. Phase II study is being done.
Novel agents in early clinical development
Voreloxin
Voreloxin is a first-in-class anticancer quinolone deriva-
tive that intercalates DNA, inhibits topoisomerase II, and
induces apoptosis. A preliminary report on a voreloxin
trial revealed clinical activity in previously untreatedZhu et al. Journal of Hematology & Oncology 2010, 3:17
http://www.jhoonline.org/content/3/1/17
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elderly (age ≥ 60) AML patients who are unlikely to bene-
fit from standard chemotherapy[45]. In this phase II dose
optimization study, 105 patients were treated, with 93
patients evaluable. The CR + CRp rate of the 3 dose
schedules was 41%, 29%, 38%, respectively. ORR across
the 3 schedules was 35%; (Table 6). The study is still
ongoing.
Amonafide L-malate (AS1413)
Amonafide L-malate (amonafide, AS1413) is a unique
DNA intercalator. In a phase II study, 88 patients with
secondary AML were enrolled to receive amonafide and
Ara-C. Overall CR + CRi rate was 42%. CR rates among
age <60 and ≥ 60, was 39.4% and 43.6%, respectively;
among tAML and prior MDS, 40% and 44.2%, respec-
tively; for patients with intermediate and unfavorable
cytogenetics, the CR rates were 61.1% and 23.8%, respec-
tively (Table 6). This study showed that amonafide in
combination with cytarabine produced a high complete
remission rate and durable responses in both older and
younger patients with secondary AML[46].
Behenoylara-C
Behenoylara-C has three-phosphoryl in the fourth N of
Ara-C, making it more lipophilic than Ara-C. Its concen-
tration is maintained longer in the blood (especially
blood cells) and tissues. This agent is transformed into
Ara-C in the liver, spleen, kidney and leukemia cells,
which inhibits DNA synthesis. Taiichi et al studied 165
patients with untreated AML using the combination of
behenoylara-C and idarubicin. 86.7% of the patients had
CR. The patients with good or intermediate risk factors
had remarkable improvements. The study showed that
the treatment is effective and safe [47] (Table 6).
Lenalidomide
Lenalidomide is one of the three new drugs approved by
the U.S. FDA to treat MDS [48,49]. Treatment of 5q-low-
risk MDS with LEN can achieve high rate of cytogenetic
CR. In a recent phase II study of LEN in combination
w i t h  A r a - C  a n d  d a u n o r u b i c i n  i n  h i g h  r i s k  M D S / AM L
with del 5q, 28% responded (Table 6). The results show
that LEN combined with chemotherapy in AML treat-
ment is feasible, without significant additional toxic-
ity[50].
Ribavirin
The eukaryotic translation factor, eIF4E, is overexpressed
in AML, and is associated with poor prognosis. Ribavirin
is clinically used as an antiviral molecule, and its struc-
ture is similar to the m(7)G cap of mRNA, thus inhibiting
eIF4E-induced export and translation of sensitive tran-
scripts. Assouline et al carried out the first clinical trial
targeting eIF4E with ribavirin in combination with AraC
in AML patients (Table 6). Clinical and molecular effi-
cacy has been evaluated in 13 patients. The treatment
was well tolerated by all patients. No hemolytic anemia
was seen. There was one complete remission, two partial
remissions, two blast responses and four patients with
stable disease. Unfortunately, all patients eventually
acquired resistance to therapy and eventually relapsed.
Hence, the novel therapies combined with ribavirin are
being sought to overcome resistance and prolong remis-
sion[51].
ARRY-520
The kinesin spindle protein (KSP) plays a major role for
the assembly of a normal bipolar spindle and is also
required for cell cycle progression through mitosis.
ARRY-520 is a potent, selective inhibitor of KSP. Thirty-
three patients with AML were enrolled to receive differ-
ent schedule of ARRY-520: 15 in the single-dose schedule
(dose levels 2.5, 3.75, 4.5 and 5.6 mg/m2) and 18 in the
divided dose schedule (dose levels 0.8, 1.2, 1.5 and 1.8
mg/m2/day). The maximal tolerated dose (MTD) was 4.5
mg/m2 for the single-dose schedule with the dose-limit-
ing toxicity (DLT) of grade 3 mucositis. The MTD was 1.5
mg/m2/day (cumulative dose per cycle of 4.5 mg/m2) for
the divided dose schedule, with DLTs being grade 3
mucositis, hand-foot syndrome and hyperbilirubinemia.
ARRY-520 was well tolerated. Four of 33 patients (12%)
showed at least 50% reduction in bone marrow blasts
(Table 6). Therefore, ARRY-520 showed promising clini-
cal activity and was well tolerated in both schedules[52].
AZD1152
Aurora B kinase plays a major role in regulating mitosis
and is overexpressed in AML. AZD1152 is a highly
potent and selective inhibitor of aurora B kinase. It has
been shown to inhibit tumor growth in vivo. A phase I/II
study was conducted to assess the safety and efficacy of
Table 3: Farnesyl-transferase inhibitor in clinical trials
inhibitors Other 
agents
Disease Dosage Clinical 
trails
No Pts Response Reference
Tipifarnib Bortezomib
1.0 mg/m2
Elderly or 
relapsed 
AML
300-600 mg 
bid, ×21d
Phase II 80 CR: 11% [30]
Tipifarnib +/- 
etoposide
Elderly 
untreated 
AML
Phase II 107 Safe [31]Zhu et al. Journal of Hematology & Oncology 2010, 3:17
http://www.jhoonline.org/content/3/1/17
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AZD1152 in patients aged >18 years with advanced AML
(Table 6). The MTD of AZD1152 was defined as 1200 mg
in patients with relapsed AML, and an overall clinical
response rate (CR+CRi+PR) of 23% was observed [53].
AZD6244
AZD6244 is one of the orally bioavailable small molecule
inhibitors of MEK kinase [54,55]. AZD6244 was studied
in 47 relapsed or refractory AML in a phase II multi-
center clinical study [56]. Among these patients, FLT3
ITD or TKD mutation was positive in 10, negative in 36,
mutational status was unknown in 1. Median number of
prior therapies for AML and/or MDS was 2 (range, 0-6).
The AZD6244 dose was 100 mg twice daily; 42 pts were
evaluable. Median number of cycles administered was 1
(range, 1-9). AZD6244 related serious adverse events
included fatigue, nausea and dehydration, occurring in
7%, 5% and 5%, respectively. Minor responses were seen,
no CR was reported. The study showed that the oral MEK
inhibitor AZD6244 is tolerable in AML. Further investi-
gation of AZD6244 in combination with drugs that target
other critical signaling/transcriptional pathways in AML
is being considered.
Terameprocol
The inhibitor of apoptosis protein (IAP), survivin, is a key
regulator of cell cycles. In leukemic cells, survivin is
involved in leukemia cell survival and resistance to che-
motherapeutics and Flt-3 inhibitors. A clinical trial with
terameprocol (EM-1421), a novel survivin and cdc2
( C D K 1 )  i n h i b i t o r ,  w a s  d o n e  i n  p a t i e n t s  w i t h  a d v a n c e d
hematological malignancies (Table 6). In a phase I dose-
finding trial, 16 patients with advanced, relapsed or
refractory hematological malignancies were treated with
1000, 1500 or 2200 mg of intravenous terameprocol 3×/
week (wk) for 2 of 3 wks. The MTD was found to be 1500
mg 3×/week for 2 of 3 wks [57].
Conclusions and future directions
Prognostic markers, such as NPM1, Flt3-ITD, and cyto-
genetic abnormalities have made it possible to prospec-
tively formulate aggressive treatment plans for
unfavorable AML. However, the long-term survival of
AML with unfavorable factors remains unsatisfactory.
Combination of azacytidine and vorinostat showed sur-
prisingly high response rate. Prolonged survival without
curing high risk MDS/AML patients with azacytidine
therapy suggests that disease modification instead of cure
of AML patients may be an alternative goal of treating
elderly patients not suitable for aggressive therapy. New
regimens and novel agents targeting specific pathways
reviewed in this report may bring AML treatment into a
new era.
Table 4: Histone deacetylase inhibitors in clinical trials
Study 
Agents
Other 
agents
Disease Dosage Clinical 
trails
No Pts Response Reference
Vorinostat Idarubicin, 
Cytarabine
untreated 
AML
500 mg po 
tid d1-3
Phase II 52 CR/CRp: 
80%
[37]
Vorinostat decitabine untreated, 
relapsed 
AML
400 mg qd, 
po 1-7d or 
1-14d
Phase I/II 72 MTD not 
reached
[38]
Abbreviations: CR: complete remission; CRp: CR without platelet recovery; MTD: maximal tolerated dose;
Table 5: DNA Methyltransferase inhibitors in clinical trials
Study Agents Other agents Disease Dosage Clinical trails No Pts Response Reference
decitabine GO Elderly, untreated 
AML
20 mg/m2 IV ×5d, GO 
3 mg/m2 IV × 1 d 5
Phase II 33 CR/CRp: 42% [39]
decitabine GO Relapsed and 
refractory AML
20 mg/m2 IV ×5d retrospective 79 CR/CRp: 21% [40]
Azacytidine Elderly relapsed and 
refractory AML
75 mg/m2/d IV, d1-7 retrospective 184 CR/CRi: 10% [41]
Azacytidine gemtuzumab 
ozogamicin (GO)
high-risk AML 75 mg/m2/d IV, d1-7 retrospective 56 CR/CRi: 10% [42]
Azacytidine Bortezomib Relapsed and 
refractory AML
75 mg/m2/d IV, d1-7 Phase I 23 CR/CRi: 21% [43]
Abbreviations: GO: gemtuzumab ozogamycin; CR: complete remission; CRi: CR with incomplete count recovery; CRp: CR without platelet recovery; 
MTD: maximal tolerated dose;Zhu et al. Journal of Hematology & Oncology 2010, 3:17
http://www.jhoonline.org/content/3/1/17
Page 8 of 10
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
XZ and DL are involved in concept design. All authors participated in data col-
lection, drafting and critically revising the manuscript.
Acknowledgements
This work was partly supported by New York Medical College Blood Diseases 
Fund.
Author Details
1Department of Hematology, First Hospital of Quanzhou Affiliated to Fujian 
Medical University, Quanzhou, 362000, China and 2Division of Hematology and 
Oncology, New York Medical College, Valhalla, NY 10595, USA
References
1. Dillman RO, Davis RB, Green MR, Weiss RB, Gottlieb AJ, Caplan S, et al.: A 
comparative study of two different doses of cytarabine for acute 
myeloid leukemia: a phase III trial of Cancer and Leukemia Group B.  
Blood 1991, 78:2520-2526.
2. Larson RA: Is modulation of multidrug resistance a viable strategy for 
acute myeloid leukemia?  Leukemia 2003, 17:488-491.
3. Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL, et al.: Dose 
Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With 
and Without Multidrug Resistance Modulation With PSC-833 in 
Untreated Adults With Acute Myeloid Leukemia Younger Than 60 
Years: Final Induction Results of Cancer and Leukemia Group B Study 
9621.  J Clin Oncol 2004, 22:4290-4301.
4. Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S, et al.: 
Randomized Study of Intensified Anthracycline Doses for Induction 
and Recombinant Interleukin-2 for Maintenance in Patients With Acute 
Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study.  
J Clin Oncol 2010, 28:808-814.
5. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al.: 
Anthracycline dose intensification in acute myeloid leukemia.  N Engl J 
Med 2009, 361:1249-1259.
6. Lowenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, 
Ferrant A, et al.: High-dose daunorubicin in older patients with acute 
myeloid leukemia.  N Engl J Med 2009, 361:1235-1248.
7. Rowe JM: Optimal induction and post-remission therapy for AML in 
first remission.  Hematology 2009, 2009:396-405.
8. Feldman EJ, Lancet J, Kolitz JE, Ritchie E, List AF, Asatiani E, et al.: Phase I 
Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed 
Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in 
Advanced Leukemias.  Blood 2008, 112:. abstract no. 2984.
9. Lancet JE, Feldman E J, Kolitz J E, Tallman M S, Hogge D E, Komrokji R S, et 
al.: Phase IIb Randomized Study of CPX-351 Vs. Conventional 
Cytarabine + Daunorubicin in Newly Diagnosed AML Patients Aged 60-
75: Safety Report.  Blood 2009, 114:Abstract No1033.
10. Kell WJ, Burnett AK, Chopra R, Yin JAL, Clark RE, Rohatiner A, et al.: A 
feasibility study of simultaneous administration of gemtuzumab 
ozogamicin with intensive chemotherapy in induction and 
consolidation in younger patients with acute myeloid leukemia.  Blood 
2003, 102:4277-4283.
11. Burnett AK, Kell W, Goldstone AH: The Addition of Gemtuzumab 
Ozogamicin to Induction Chemotherapy for AML Improves Disease 
Free Survival without Extra Toxicity: Preliminary Analysis of 1115 
Patients in the MRC AML15 Trial.  Blood 2006, 108:. Abstract No. 13.
12. Borthakur G, Faderl S, Verstovsek S, Jones D, Gandhi V, Estrov Z, et al.: 
Clinical and Molecular Response in Core Binding Factor Acute 
Myelogenous Leukemia with Fludarabine, Cytarabine, G-CSF and 
Gemtuzumab Ozogamicin.  Blood 2009, 114:. Abstract No.2056.
13. Paolini S, Parisi S, Candoni A, Piccaluga PP, Gottardi M, Laterza C, et al.: Four 
Drugs Induction Therapy (fludarabine, cytarabine, idarubicin and 
gemtuzumab ozogamycin) for the Treatment of Elderly Acute Myeloid 
Leukemia Patients.  Blood 2009, 114:. Abstract No.1027.
14. Larson S, Campbell N, Huo D, Artz A, Zhang Y, Gajria D, et al.: High Dose 
Cytarabine (HiDAC) and Mitoxantrone (MITO) Is An Effective Induction 
Therapy for High-Risk Acute Myeloid Leukemia.  Blood 2009, 114:. 
Abstract No.1048.
15. Miyawaki S, Hatsumi N, Yamauchi T: Phase 2 Study of FLAGM 
(Fludarabine+High-Dose Ara-C +G-CSF+Mitoxantrone) for Relapsed or 
Received: 9 March 2010 Accepted: 23 April 2010 
Published: 23 April 2010
This article is available from: http://www.jhoonline.org/content/3/1/17 © 2010 Zhu et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Journal of Hematology & Oncology 2010, 3:17
Table 6: Novel agents in clinical trials
Study Agents Other agents Disease Dosage Clinical trails No Pts Response Reference
CPX-351
(liposomal cytarabine: 
daunorubicin at 5:1)
Elderly 
untreated AML
100 u/m2 D1,3,5 Phase IIb 45 acceptable 
toxicity and 
comparable to 
standard 
regimen
[9]
Voreloxin (anticancer 
quinolone derivative)
Elderly 
untreated AML
72 mg/m2 qw × 3 Phase II 105 CR/CRp: 47% [45]
Amonafide (AS1413) Cytarabine Secondary AML 600 mg/m2/d IV d1-5 Phase II 88 CR/CRi: 42% [46]
behenoylara-C Idarubicin
Etoposide
untreated AML 300-350 mg/m2
× 10d
Phase II 165 CR: 87% [47]
Lenalidomide Cytarabine, 
Daunorubicin
5q-AML/MDS 10 mg/d po d1-21 Phase I/II 18 CR/CRi: 47% [50]
Ribavirin Cytarabine AML 13 CR:7% [51]
ARRY-520 idarubicin refractory AML 0.8-5.6 mg/m2 IV Phase I 33 MTD: 4.5 mg/m2 [52]
AZD1152 relapsed AML 50 mg-1600 mg Phase I/II 64 MTD: 1200 mg [53]
AZD6244 AML 100 mg po bid Phase II 47 Feasible 
treatment
[56]
Terameprocol relapsed and 
refractory AML
1000-2200 mg iv, 3/w, ×2-3w Phase I/II 16 MTD: 1500 mg [57]
Abbreviations: CR: complete remission; CRi: CR with incomplete count recovery; CRp: CR without platelet recovery; MTD: maximal tolerated dose;Zhu et al. Journal of Hematology & Oncology 2010, 3:17
http://www.jhoonline.org/content/3/1/17
Page 9 of 10
Refractory Acute Myeloid Leukemia (AML): A Report From the Japan 
Adult Leukemia Study Group (JALSG).  Blood 2009, 114:. Abstract 
No.1058.
16. Prébet T, Charbonnier A, Etienne A, D'Incan E, Fürst S, Blaise D: A Direct 
Comparison of High Dose Cytarabineto Combination of Gemtuzumab 
and High Dose Cytarabine for Acute Myeloid Leukemia Patients in First 
Relapse Confirmed the Benefit of Gemtuzumab Based Regimens.  
Blood 2009, 114:. Abstract No.2051.
17. Scappini B, Gianfaldoni G, Salvatore P, Susini M C, Izzo T, Mannelli F, et al.: 
High Dose Cytarabine, Clofarabine and Gemtuzumab Ozogamicin 
(CLAC-MYL) in Relapsed or Refractory AML Patients.  Blood 2009, 114:. 
Abstract No.1060.
18. Erba HP, Faderl S, Claxton D F, Arellano M, Lyons R M, Kovacsovics T J, et al.: 
Single-Agent Clofarabine Produces Durable Remissions in Patients 
with Acute Myelogenous Leukemia (AML) Who Are = 70, Have 
Intermediate or Unfavorable Cytogenetics, Antecedent Hematological 
Disorders (AHD), or 2 or More Unfavorable Prognostic Factors.  Blood 
2009, 114:. Abstract No.2083.
19. Becker PS, Estey E, Petersdorf S, Storer B E, Appelbaum F R: G-CSF Priming, 
Clofarabine and High Dose Cytarabine (GCLAC) for Relapsed or 
Refractory Acute Myeloid Leukemia (AML).  Blood 2009, 114:. Abstract 
No.2068.
20. Foster MC, Amin C, Voorhees P M, Van Deventer H W, Richards K L, 
Anastasia I, et al.: A Phase I, Dose Escalation Study of Clofarabine in 
Combination with Fractionated Gemtuzumab Ozogamicin in Relapsed 
and Refractory Acute Myeloid Leukemia (AML).  Blood 2009, 114:. 
Abstract No.2048.
21. Parikh SA, Hagop K, Garcia-Manero G, Jabbour E, Kadia T, Ravandi F, et al.: 
Clofarabine Plus Low-Dose Cytarabine Induction Followed by 
Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating 
with Decitabine as Frontline Therapy for Patients (pts) with Acute 
Myeloid Leukemia (AML) = 60 Years (yrs).  Blood 2009, 114:. Abstract 
No.2058.
22. Kantarjian HM, Garcia-Manero G, Luger S, Venugopal P, Maness L J, 
Wetzler M, et al.: A Randomized Phase 2 Study of Sapacitabine, An Oral 
Nucleoside Analogue, in Elderly Patients with AML Previously 
Untreated or in First Relapse.  Blood 2009, 114:. Abstract No.1061.
23. O'Brien S, Rizzieri D A, Vey N, Ravandi F, Krug U O, Sekeres M A, et al.: 
APhase II Multicentre Study with Elacytarabine as Second Salvage 
Therapyin Patients with AML.  Blood 2009, 114:. Abstract No.1042.
24. Gregory TK, Wald D, Chen Y, Vermaat JM, Xiong Y, Tse W: Molecular 
prognostic markers for adult acute myeloid leukemia with normal 
cytogenetics.  J Hematol Oncol 2009, 2:23.
25. Metzelder S, Scholl S, Matthias K, Reiter A, Meyer R G, Heinicke T, et al.: 
Compassionate Use of Sorafenib in Relapsed and Refractory Flt3-ITD 
Positive Acute Myeloid Leukemia.  Blood 2009, 114:. Abstract No.2060.
26. Pemmaraju N, Kantarjian H M, Ravandi F, Garcia-Manero G, Gautam B, 
Parikh S A, et al.: FLT3 Inhibitor Therapy for Patients with 
Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia 
(AML): Impact On Survival According to FLT3 Status.  Blood 2009, 114:. 
Abstract No. 1026.
27. Schroeder T, Saure C, Bruns I, Zohren F, Czibere A G, Safaian N N, et al.: 
Clinical Efficacy of Sorafenib in Patients with Acute Myeloid Leukemia 
(AML) and Activating FLT3-Mutations.  Blood 2009, 114:. Abstract 
No.2057.
28. Al-Kali A, Jones D, Cortes J, Faderl S, Xue A, Garcia-Manero G, et al.: 
Patterns of Molecular Response to and Relapse After Combination of 
Sorafenib, Idarubicin, and Cytarabine in Patients with Newly 
Diagnosed FLT3-Mutant Acute Myeloid Leukemia (AML).  Blood 2009, 
114:. Abstract No.2079.
29. Baum K, Ren R: Effect of Ras Inhibition in Hematopoiesis and BCR/ABL 
Leukemogenesis.  Journal of Hematology & Oncology 2008, 1:5.
30. Paolini S, Ottaviani E, Parisi S, Salmi F, Lama B, Curti A, et al.: RASGRP1/APTX 
Ratio Strongly Correlates with Clinical Response and Survival in AML 
Patients Treated with Tipifarnib-Bortezomib Combination.  Blood 2009, 
114:. Abstract No.1028.
31. Feldman EJ, Ritchie E, Gergis U, Mayer S, Scandura J M, Christos P J, et al.: 
Evaluation of Alternative, "Low-intensity" Induction Regimens in 
Elderly Adults with Acute Myeloid Leukemia (AML).  Blood 2009, 114:. 
Abstract No.2066.
32. Cang S, Ma Y, Liu D: New clinical developments in histone deacetylase 
inhibitors for epigenetic therapy of cancer.  J Hematol Oncol 2009, 2:22.
33. Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM, et al.: 
Vorinostat in solid and hematologic malignancies.  J Hematol Oncol 
2009, 2:31.
34. Tan J, Cang S, Ma Y, Petrillo RL, Liu D: Novel histone deacetylase 
inhibitors in clinical trials as anti-cancer agents.  J Hematol Oncol 2010, 
3:5.
35. Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, Hoshino K, Quintas-
Cardama A, Richon VM, et al.: Antileukemia activity of the combination 
of an anthracycline with a histone deacetylase inhibitor 2.  Blood 2006, 
108:1174-1182.
36. Shiozawa K, Nakanishi T, Tan M, Fang HB, Wang WC, Edelman MJ, et al.: 
Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) 
combined with cytosine arabinoside and etoposide for treatment of 
acute leukemias 1.  Clin Cancer Res 2009, 15:1698-1707.
37. Garcia-Manero G, Tambaro F P, Bekele N B, Jabbour E, Ravandi F, Yang H, et 
al.: Phase II Study of Vorinostat in Combination with Idarubicin (Ida) 
and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous 
Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).  
Blood 2009, 114:. Abstract No.1055.
38. Kirschbaum M, Ivana G, Goldberg S L, Kujawski L, Atallah E, Marks P, et al.: 
Vorinostat in Combination with Decitabine for the Treatment of 
Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or 
Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study.  
Blood 2009, 114:. Abstract No.2089.
39. Borthakur G, Garcia-Manero G, Estrov Z, Konopleva M, Burger J A, Thomas 
De A, et al.: Phase 2 Study of Decitabine and Gemtuzumab Ozogamicin 
in Acute Myelogenous Leukemia and High-Risk Myelodysplastic 
Syndrome-Outcome in Previously Untreated Patients.  Blood 2009, 114:. 
Abstract No.1053.
40. Ritchie EK, Arnason J, Feldman E J, Gergis U S, Mayer S A, Ippoliti C, et al.: 
Decitabine-Based Salvage Therapy in Adults with Acute Myeloid 
Leukemia.  Blood 2009, 114:. Abstract No.2063.
41. Itzykson R, Thepo S, Reche C, Delaunay J, Quesnel B: Azacytidine in 
Refractory or Relapsed AML After Intensive Chemotherapy (IC): Results 
of the French ATU Program.  Blood 2009, 114:. Abstract No.1054.
42. Michaelis LC, Shafer D, Barton K, Rodriguez T, Smith S, Stiff P, et al.: 
Azacitadine and Low-Dose Gemtuzumab Ozogamicin for the 
Treatment of Poor-Risk Acute Myeloid Leukemia (AML) and 
Myelodysplastic Syndromes (MDS), Including Relapsed, Refractory 
Disease.  Blood 2009, 114:. Abstract No.1034.
43. Blum W, Klisovic R B, Walker A, Garzon R, Liu S, Schaaf L J, et al.: Epigenetic 
Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a 
Phase I Study of Bortezomib in Combination with 5-Azacytidine in 
Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML).  
Blood 2009, 114:. Abstract No.2065.
44. Silverman LR, Verma A, Odchimar-Reissig R, LeBlanc A, Najfeld V, Gabrilove 
J, et al.: A Phase I Trial of the Epigenetic Modulators Vorinostat, in 
Combination with Azacitidine (azaC) in Patients with the 
Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): 
A Study of the New York Cancer Consortium.  ASH Annual Meeting 
Abstracts 2008, 112:3656.
45. Ravandi F, Kantarjian H M, Cripe L D, Maris M, Cooper M, Dakhil S R, et al.: A 
Phase 2 Dose Regimen Optimization Study of Three Schedules of 
Voreloxin as Single Agent Therapy for Elderly Patients with Newly 
Diagnosed Acute Myeloid Leukemia.  Blood 2009, 114:. Abstract 
No.1037.
46. Erba HP, O'Donnell M, Allen S L, Baer M R, Powell B L, Stone R M, et al.: 
Amonafide L-Malate (AS1413) in Combination with Cytarabine Is 
Equally Effective in Older and Younger Patients with Secondary Acute 
Myeloid Leukemia (AML); Final Data From a Phase II Study.  Blood 2009, 
114:. Abstract No.1047.
47. Kyo T, Kimura A, Kyo K, Yoshida N, Asaoku H, Iwato K, et al.: High 
Remission Rates and Long-Term Survival in a High Percentage of 
Patients Achieved by Intensive Chemotherapy for AML and Further 
Improvement of Supportive Care.  Blood 2009, 114:. Abstract No.1052.
48. Raza A, Galili N, Callander N, Ochoa L, Piro L, Emanuel P, et al.: Phase 1-2a 
multicenter dose-escalation study of ezatiostat hydrochloride 
liposomes for injection (Telintra(R), TLK199), a novel glutathione 
analog prodrug in patients with myelodysplastic syndrome.  J Hematol 
Oncol 2009, 2:20.Zhu et al. Journal of Hematology & Oncology 2010, 3:17
http://www.jhoonline.org/content/3/1/17
Page 10 of 10
49. Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, et al.: Mechanism of 
action of lenalidomide in hematological malignancies.  J Hematol Oncol 
2009, 2:36.
50. Ades L, Stamatoullas A, Raffoux E, Prebet T, Lenain P, Guieze R, et al.: 
Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) in AML 
and Higher Risk MDS with Del 5q. Interim Results of a Phase I/II Study.  
Blood 2009, 114:. Abstract No.1049.
51. Assouline SE, Cocolakis E, Rousseau C, Culjkovic B, Beslu N, Amri A, et al.: 
Targeting the Oncogene eIF4E with Ribavirin: A Novel Therapeutic 
Avenue in Acute Myeloid Leukemia.  Blood 2009, 114:. Abstract No.2085.
52. Garcia-Manero G, Khoury J H, Borthakur G, Ravandi F, Kadia T, Estrov Z, et 
al.: A Phase 1 Dose-Escalation Study of the Novel KSP Inhibitor ARRY-
520 in Advanced Leukemias.  Blood 2009, 114:. Abstract No.2047.
53. Lowenberg B, Rousselot P, Martinelli G, Goudie A, Stockman P, Kantarjian 
H: Phase I/II Study to Assess the Safety and Efficacy of the Aurora B 
Kinase Inhibitor, AZD in Patients with Advanced Acute Myeloid 
Leukemia.  Blood 1152, 114:. Abstract No.2080.
54. Fremin C, Meloche S: From basic research to clinical development of 
MEK1/2 inhibitors for cancer therapy.  Journal of Hematology & Oncology 
2010, 3:8.
55. Tai YT, Kim K, Li XF, Fulciniti M, Song W, Nahar S, et al.: Targeting MEK1/2 
Signaling Cascade by AS70 a Novel Selective MEK1/2 Inhibitor, Induces 
Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo.  ASH Annual 
Meeting Abstracts 2009, 114:3848.
56. Odenike O, Curran E, Iyengar N, Popplewell L, Kirschbaum M, Erba H P, et 
al.: Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced 
Acute Myeloid Leukemia (AML).  Blood 2009, 114:. Abstract No.2081.
57. Tibes R, McDonagh K T, Lekakis L, Frazer N, Mohrland S, Dawn B, et al.: 
Phase I Study of the Novel Survivin and cdc2/CDK1 Inhibitor 
Terameprocol in Patients with Advanced Leukemias.  Blood 2009, 114:. 
Abstract No.1039.
doi: 10.1186/1756-8722-3-17
Cite this article as: Zhu et al., Novel agents and regimens for acute myeloid 
leukemia: 2009 ASH annual meeting highlights Journal of Hematology & 
Oncology 2010, 3:17